Improving Stem Cell and Cord Blood Transplants
Hematopoietic Stem Cell And Cord Blood Transplantation
This work aims to make stem cell and cord blood transplants safer and more effective for people with serious blood disorders, especially by reducing the risk of relapse.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11173954 on NIH RePORTER |
What this research studies
This research focuses on improving hematopoietic cell transplantation (HCT) for life-threatening blood disorders, with a primary goal of preventing the disease from returning after transplant. Researchers are exploring how specific genetic markers, known as HLA genes, influence the success of a transplant and the likelihood of relapse. By understanding these genetic interactions, especially in diverse patient populations, the team hopes to identify better donor matches and develop new strategies to keep the disease from coming back. This could lead to more successful transplants and better long-term health for patients.
Who could benefit from this research
Good fit: Patients with life-threatening blood disorders who are candidates for or have undergone hematopoietic cell transplantation, particularly those from diverse racial and ethnic backgrounds, would be the focus of this research.
Not a fit: Patients who do not have blood disorders requiring stem cell transplantation or who are not at risk for post-transplant relapse would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could significantly lower the risk of disease relapse after stem cell transplants and improve long-term survival for patients with blood disorders.
How similar studies have performed: While improved GVHD prevention regimens have increased transplant safety, the specific focus on HLA class I genes and relapse mechanisms is presented as a new paradigm in HCT.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Petersdorf, Effie W — Fred Hutchinson Cancer Center
- Study coordinator: Petersdorf, Effie W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.